%0 Journal Article
%T The Diagnosis and Treatment of Pancreatic NEN-G3-A Focus on
Clinicopathological Difference of NET-G3 and NEC G3 | Insight Medical Publishing
%A Chigusa Morizane
%A Kazuo Hara
%A Nobumasa Mizuno
%A Susumu Hijioka
%A Takuji Okusaka
%A Waki Hosoda
%J January 2019
%D 2018
%X Pancreatic neuroendocrine carcinoma (panNEC; pancreatic neuroendocrine neoplasm NEN-G3) is expected to be divided into neuroendocrine tumor-G3 and neuroendocrine carcinoma-G3 in the World Health Organization 2017 classification of tumors of endocrine organs. The distinction is clinically important£¿£¿£¿because the response to chemotherapy differs between the two. Evidence is accumulating on the molecular features of NET-G3, which supports the view that NET-G3 is more closely related to well-differentiated NET. Several molecular markers can be useful in predicting the effectiveness of platinum-based chemotherapies, including high Ki67 labeling index, loss of Rb expression, or KRAS mutation. However, appropriate chemotherapy for NET-G3 remains unclear. Appropriate classification of NET-G3/NEC-G3 and the adequacy of standard treatments depending on this classification are expected in the future with the accumulation of further cases.
%U http://pancreas.imedpub.com/the-diagnosis-and-treatment-of-pancreatic-neng3a-focus-onclinicopathological-difference-of-netg3-and-nec-g3.php?aid=21170